Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Company Description At Swissquote, we’re all in. All in to shake things up. All in to build the bank people actually want to use. All in to make finance less boring — and a lot more